Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
We aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO. Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients. The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P < .05). From group 1 to group 3, BMI, FM, FM index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and irisin decreased (P < .05). A positive correlation was found between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (r = 0.303, P = .004 vs. r = −0.491, P < .001). Irisin remained an important predictor of SO, even after adjusting for confounding variables (OR:1.105; 95% CI:0.965–1.338, P = .002). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL (specificity = 78.1%, sensitivity = 75.8%). In addition, A1c was an independent risk factor for SO development (OR:1.358, P = .055). This study showed that low irisin levels (<9.49ng/mL) and poor glycemic control in T2DM patients were an independent risk factor, especially for SO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 1×
“1 is defined as a generalized loss of muscle mass and strength that may cause health problems.([1,2]) Patients with type 2 diabetes mellitus (T2DM) have a higher risk.”
BackgroundJanssen, I., Heymsfield, S. B., & Ross, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50216.x · Cited by 3,139 · cited 1×
“6% for women.([27]) FFM index (FFMI), FFM/height(2) (kg/m(2)), and FM index (FMI) were calculated as FM/height(2) (kg/m(2)).”
MethodMoreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones, F., Ricart, W., & Fernández-Real, J. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2749 · Cited by 788 · cited 4×
“Multiple logistic regression tistically significant. gait speed, HGS = hand grip strength, OR = odds ratio, Total-C = total cholesterol. levels were negatively correlated with BMI, WHR, and FM.[42] Furthermore, a positive correlation has been reported between irisin levels and muscle mass and strength in humans and a…”
BackgroundInfluentialExcessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778 · cited 3×
“Several studies have revealed an association between diabetes and sarcopenia, and the prevalence of sarcopenia increased 2–3 times in patients with diabetes than in healthy controls.([3,34]) However, information on the prevalence of SO in patients with T2DM is limited.”
BackgroundDecreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., & Newman, A. B. (2006) · Diabetes · doi:10.2337/db05-1183 · Cited by 751
Sarcopenic obesity: a critical appraisal of the current evidence
Prado, C. M. M., Wells, J. C. K., Smith, S. R., Stephan, B. C. M., & Siervo, M. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.06.010 · Cited by 589 · cited 11×
“Myostatin is a negative regulator of muscle mass, as well as a potential biomarker that contributes to both metabolic and anabolic defects in SO.”
BackgroundMethodInfluentialLim, S., Kim, J. H., Yoon, J. W., Kang, S. M., Choi, S. H., Park, Y. J., Kim, K. W., Lim, J. Y., Park, K. S., & Jang, H. C. (2010) · Diabetes Care · doi:10.2337/dc10-0107 · Cited by 588 · cited 2×
“1% in women by ASM (%) defined sarcopenia.([5]) Low et al([37]) reported the prevalence of SO defined by using the FM/FFM ratio as 19.”
BackgroundMethodPrevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes
Kim, T. N., Park, M. S., Yang, S. J., Yoo, H. J., Kang, H. J., Song, W., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2310 · Cited by 585
Mayhew, A. J., Amog, K., Phillips, S., Parise, G., McNicholas, P. D., de Souza, R. J., Thabane, L., & Raina, P. (2019) · Age and Ageing · doi:10.1093/ageing/afy106 · Cited by 478 · cited 1×
“The prevalence of sarcopenia increases with age.([33]) Several studies have revealed an association between diabetes and sarcopenia, and the prevalence of sarcopenia increased 2–3 times in patients with diabetes than in healthy controls.”
BackgroundKurdiova, T., Balaz, M., Vician, M., Maderova, D., Vlcek, M., Valkovic, L., Srbecky, M., Imrich, R., Kyselovicova, O., Belan, V., et al. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2013.264655 · Cited by 401 · cited 1×
“Furthermore, a positive correlation has been reported between irisin levels and muscle mass and strength in humans and a negative correlation between irisin levels and fasting blood glucose levels.([43]) In our study, irisin levels were significantly lower in patients with sarcopenia.”
Background
Cited by
Exercise therapy for people with sarcopenic obesity: myokines and adipokines as effective actors
Alizadeh Pahlavani, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.811751 · Cited by 145
Sbrignadello, S., Göbl, C., & Tura, A. (2022) · Nutrients · doi:10.3390/nu14091864 · Cited by 68
Adipose–Muscle Crosstalk in Age-Related Metabolic Disorders: The Emerging Roles of Adipo-Myokines
Fang, P., She, Y., Yu, M., Min, W., Shang, W., & Zhang, Z. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101829 · Cited by 62
Metadata
- Authors
- Oguz, A., Sahin, M., Tuzun, D., Kurutas, E. B., Ulgen, C., Bozkus, O., & Gul, K.
- Venue
- Medicine
- Published
- 2021-07-02
- Volume
- 100
- Issue
- 26
- Pages
- e26529
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- OpenAlex
- W3175901928
- Cited by
- 46
- References
- 18
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study. https://app.cochat.ai/papers/10.1097/md.0000000000026529
- The paper
- Oguz, A., Sahin, M., Tuzun, D., Kurutas, E. B., Ulgen, C., Bozkus, O., & Gul, K. (2021). Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study. Medicine. https://doi.org/10.1097/md.0000000000026529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.